title: Immunoenhancing properties and antiviral activity of 7-deazaguanosine in mice.
abstract: The nucleotide analog 7-deazaguanosine has not previously been reported to possess biological (antiviral or antitumor) properties in cell culture or in vivo. Up to 10(5) U of interferon per ml was detected in mouse sera 1 to 4 h following oral (200-mg/kg of body weight) and intraperitoneal (50-mg/kg) doses of the compound. 7-Deazaguanosine also caused significant activation of natural killer and phagocytic cells but did not augment T- and B-cell blastogenesis. Intraperitoneal treatments of 50, 100, and 200 mg/kg/day administered 24 and 18 h before virus inoculation were highly protective in mice inoculated with lethal doses of Semliki Forest or San Angelo viruses. Less but still significant survivor increases were evident in treated mice infected with banzi or encephalomyocarditis viruses. In most cases, the degree of antiviral activity was similar to that exhibited by the biological response modifier 7-thia-8-oxoguanosine. 7-Thia-8-oxoguanosine was more potent than 7-deazaguanosine against encephalomyocarditis virus in mice, however. Oral efficacy was achieved with 7-deazaguanosine treatments of greater than or equal to 100 mg/kg against all virus infections, whereas 7-thia-8-oxoguanosine is reported to be devoid of oral activity in rodents. Thus, 7-deazaguanosine represents the first reported orally active nucleoside biological response modifier exhibiting broad-spectrum antiviral activity against particular types of RNA viruses.
authors.affiliation: Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan 84322-5600.
authors.forename: D F
authors.initials: DF
authors.lastname: Smee
authors.forename: H A
authors.initials: HA
authors.lastname: Alaghamandan
authors.forename: J
authors.initials: J
authors.lastname: Gilbert
authors.forename: R A
authors.initials: RA
authors.lastname: Burger
authors.forename: A
authors.initials: A
authors.lastname: Jin
authors.forename: B S
authors.initials: BS
authors.lastname: Sharma
authors.forename: K
authors.initials: K
authors.lastname: Ramasamy
authors.forename: G R
authors.initials: GR
authors.lastname: Revankar
authors.forename: H B
authors.initials: HB
authors.lastname: Cottam
authors.forename: W B
authors.initials: WB
authors.lastname: Jolley
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D000284:Administration, Oral; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D005260:Female; D006151:Guanosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity; D007274:Injections, Intraperitoneal; D007372:Interferons / Q000096:biosynthesis; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D051379:Mice; D014777:Virus Diseases / Q000188:drug therapy
chemical_list: D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D006151:Guanosine; C068218:7-deazaguanosine; D007372:Interferons